Impact of Manufacturing Procedures on CAR T Cell Functionality

Overview
This review examines how media, sera, cytokines, inhibitors, culture length and cryopreservation shape CAR T cell function. Methods that kept cells less differentiated and less exhausted gave products with higher in vivo potency, and shorter manufacturing improved tumor control in mice.
What this paper found
Ex vivo culture conditions can substantially change the quality of CAR T cell products, yet they receive less attention than genetic engineering. This review examines how media, sera and serum substitutes, cytokines, pharmacological inhibitors, culture duration and cryopreservation affect CAR T cell expansion and function. Across the studies discussed, methods that preserve less differentiated, less exhausted or less glycolytic cells generally gave products with higher in vivo anti-tumor potency. For example, human platelet lysate supported expansion at low serum concentrations where fetal bovine serum failed, and IL-7/IL-15 outperformed IL-2 over time. Shorter manufacturing gave better tumor control in mouse models. The authors note that many studies used expansion as the only readout and call for trials assessing both quantity and quality.
Note: This is a narrative review of published studies; the authors note that knowledge of manufacturing effects remains limited and that more studies, especially clinical trials, are needed.
Although extensive efforts have been spent on inventing genetic engineering methods to enhance CAR T cell potency, fewer studies to date focused on the optimization of ex vivo cell expansion conditions. — Norihiro Watanabe, Feiyan Mo, Mary Kathryn McKenna, Frontiers in Immunology
Study details
- Authors
- Norihiro Watanabe, Feiyan Mo, Mary Kathryn McKenna
- Institution
- Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, United States · Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, United States
- Journal
- Frontiers in Immunology
- Year
- 2022
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy · Solid tumor
Explore related
Full citation
Watanabe N, Mo F, McKenna MK. Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol. 2022;13:876339.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.